ME02162B - Proces prečišćavanja proteina - Google Patents
Proces prečišćavanja proteinaInfo
- Publication number
- ME02162B ME02162B MEP-2015-94A MEP9415A ME02162B ME 02162 B ME02162 B ME 02162B ME P9415 A MEP9415 A ME P9415A ME 02162 B ME02162 B ME 02162B
- Authority
- ME
- Montenegro
- Prior art keywords
- host cell
- recombinant
- recombinant protein
- seq
- extract
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 27
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 13
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims 6
- 108020003519 protein disulfide isomerase Proteins 0.000 claims 6
- 230000001580 bacterial effect Effects 0.000 claims 3
- 108010016626 Dipeptides Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 229960000583 acetic acid Drugs 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000011097 chromatography purification Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000011536 extraction buffer Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000012362 glacial acetic acid Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 102000057041 human TNF Human genes 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 238000010979 pH adjustment Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Claims (25)
1. Metod za prečišćavanje rekombinantnog proteina iz gram-negativnog bakterijskog uzorka ćelije domaćina ili njegovog ekstrakta pri čemu navedena ćelija domaćina eksprimira rekombinantni protein i rekombinantnu disulfid izomerazu DsbC; pri čemu metoda sadrži: a) podešavanje pH uzorka ćelije domaćina, ili njegovog ekstrakta do pH 5 ili manje da se istaloži rekombinantna disulfid izomeraza; i b) odvajanje istaložene rekombinantne disulfid izomeraze iz rekombinantnog proteina da se proizvede uzorak rekombinantnog proteina.
2. Metod prema patentnom zahtevu 1, pri čemu je pH uzorka ćelije domaćina ili njegovog ekstrakta podešena na pH od 4.5 ili manje.
3. Metod prema patentnom zahtevu 2, pri čemu je pH uzorka ćelije domaćina ili njegovog ekstrakta podešena na pH od 4.5 do 3.0.
4. Metod prema patentnom zahtevu 2, pri čemu je pH uzorka ćelije domaćina ili njegovog ekstrakta podešena na pH od 3 ili manje.
5. Metod prema patentnom zahtevu 4, pri čemu se u koraku a) dipeptid ćelije domaćina vezujućeg proteina je dalje istaložen i ukoraku b) dipeptid ćelije domaćina je dalje odvojen od rekombinantnog proteina.
6. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu disulfid izomeraza sadrži dodatak histidina.
7. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu je gram-negativna bakterijska ćelija domaćina E. koli.
8. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu ćelija domaćina sadrži Fkpa i/ili Skp.
9. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu u koraku a) pH uzorka ćelije domaćina ili njegov ekstrakt je podešen na pH od manje od 5 upotrebom glacijalne-ledene sirćetne kiseline.
10. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu uzorak ćelije domaćina ili njegov ekstrakt se drži na pH od 5 ili manje tokom jednog sata ili manje.
11. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu separacija u koraku b) sadrži centrifugiranje i/ili filtriranje.
12. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu nakon koraka b) metod sadrži dalji korak podvrgavanja prečišćavanju uzorka rekombinantnog proteina do hromatografije.
13. Metod prema patentnom zahtevu 11, pri čemu je hromatografija hromatografija jonske izmene.
14. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu nakon koraka b) pH uzorka rekombinantnog proteina je podešena na pH od 5 do 7.
15. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu pre koraka a) pufer za ekstrakciju je dodat uzorku ćelije domaćina ili njegovom ekstraktu i uzorak ćelije domaćina ili njegov ekstrakt je podvrgnut koraku termičke obrade.
16. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu rekombinantni protein ima pl od 6 do 9.
17. Metod prema patentnom zahtevu 16, pri čemu rekombinantni protein ima pl od 8 do 9.
18. Metod prema bilo kojem od prethodnih patentnih zahteva, pri čemu rekombinantni protein je rekombinantno antitelo.
19. Metod prema patentnom zahtevu 18, pri čemu je rekombinantno antitelo monoklonalno, humanizovano ili himerno antitelo, ili fragment od njih, kao što je vezujući fragment od njih.
20. Metod prema patentnom zahtevu 18 ili zahtevu 19, pri čemu je rekombinantno antitelo Fab ili Fab-ov fragment.
21. Metod prema bilo kojem od patentnih zahteva 18 do 20, pri čemu je rekombinantno antitelo specifično za humani TNFɑ.
22. Metod prema patentnom zahtevu 21, pri čemu antitelo sadrži teški lanac gde varijabilni domen sadrži CDR koji ima sekvencu datu u SEQ ID NO:1 za CDRH1, SEQ ID NO:2, za CDRH2 i SEQ ID NO:3 za CDRH3 i laki lanac pri čemu varijabilni domen sadrži CDR koji ima sekvencu datu u SEQ ID NO:4 za CDRL1, SEQ ID NO:5 za CDRL2 i SEQ ID NO:6 za CDRL3.
23. Metod prema patentnom zahtevu 22, pri čemu antitelo sadrži sekvencu varijabilne regije lakog lanca datu u SEQ ID NO: 7 i varijabilna regija teškog lanca je data u SEQ ID NO: 8.
24. Metod prema patentnom zahtevu 23, pri čemu je antitelo Fab fragment i sadrži teški lanac koji ima sekvencu datu u SEQ ID NO: 10 i laki lanac koji ima sekvencu datu u SEQ ID NO: 9.
25. Upotreba koraka podešavanja pH od gram-negativnog bakterijskog uzorka ćelije domaćina ili njegovog ekstrakta transformisanog ekspresonim vektorom koji kodira rekombinantni protein na pH 5 ili manje da se istaloži rekombinantna disulfid izomeraza ćelije domaćina, odvoji precipitirana rekombinantna disulfid izomeraza ćelije domaćina iz rekombinantnog proteina i proizvede prečišćeni uzorak rekombinantnog proteina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1012599.5A GB201012599D0 (en) | 2010-07-27 | 2010-07-27 | Process for purifying proteins |
| EP11745810.9A EP2598516B8 (en) | 2010-07-27 | 2011-07-27 | Process for purifying proteins |
| PCT/GB2011/001129 WO2012013930A2 (en) | 2010-07-27 | 2011-07-27 | Process for purifying proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02162B true ME02162B (me) | 2015-10-20 |
Family
ID=42752868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-94A ME02162B (me) | 2010-07-27 | 2011-07-27 | Proces prečišćavanja proteina |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9751930B2 (me) |
| EP (1) | EP2598516B8 (me) |
| JP (1) | JP5935222B2 (me) |
| KR (1) | KR101944121B1 (me) |
| CN (1) | CN103189385B (me) |
| AU (1) | AU2011284548B2 (me) |
| BR (1) | BR112013000177B1 (me) |
| CA (1) | CA2804099C (me) |
| CY (1) | CY1116526T1 (me) |
| DK (1) | DK2598516T3 (me) |
| ES (1) | ES2537877T3 (me) |
| GB (1) | GB201012599D0 (me) |
| HR (1) | HRP20150639T1 (me) |
| HU (1) | HUE026049T2 (me) |
| IL (1) | IL224044A (me) |
| ME (1) | ME02162B (me) |
| MX (1) | MX337184B (me) |
| PL (1) | PL2598516T3 (me) |
| PT (1) | PT2598516E (me) |
| RS (1) | RS54085B1 (me) |
| SG (2) | SG196862A1 (me) |
| SI (1) | SI2598516T1 (me) |
| SM (1) | SMT201500142B (me) |
| WO (1) | WO2012013930A2 (me) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2993231T1 (sl) | 2009-09-24 | 2018-10-30 | Ucb Biopharma Sprl | Bakterijski sev za izražanje rekombinantnega proteina, ki ima proteazno deficientno DEGP-zadrževalno šaperonsko aktivnost, ter onesposobljena gena TSP in PTR |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| WO2013007388A1 (en) | 2011-07-13 | 2013-01-17 | Ucb Pharma, S.A. | Bacterial host strain expressing recombinant dsbc |
| GB201208367D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| KR102065355B1 (ko) * | 2012-05-31 | 2020-01-13 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 단백질 제조물 내의 응집체 양 감소를 위한 혼합 다관능 표면들의 사용 방법 |
| JP6297029B2 (ja) * | 2012-05-31 | 2018-03-20 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 多様な官能基を有する粒子による免疫グロブリンｇ調製物のクロマトグラフィー精製 |
| BR112017009152A2 (pt) * | 2014-11-05 | 2018-03-06 | Genentech Inc | métodos de produção de proteínas de duas cadeias em bactérias |
| JP6807327B2 (ja) * | 2014-12-22 | 2021-01-06 | ユーシービー バイオファルマ エスアールエル | タンパク質製造 |
| ES3046837T3 (en) | 2014-12-22 | 2025-12-02 | UCB Biopharma SRL | Method of protein manufacture |
| CA2978256A1 (en) * | 2015-03-06 | 2016-09-15 | Genentech, Inc. | Ultrapurified dsba and dsbc and methods of making and using the same |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
| CN114829578B (zh) * | 2019-08-05 | 2024-09-24 | 瓦克化学股份公司 | 用于在发酵方法中释放重组蛋白的细菌菌株 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US5030570A (en) | 1988-06-30 | 1991-07-09 | The Eunice Kennedy Shriver Center For Mental Retardation | DNA encoding and method of expressing human monoamine oxidase type A |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9215540D0 (en) | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| US6027888A (en) * | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| ATE343790T1 (de) | 1999-06-29 | 2006-11-15 | Siga Technologies Inc | Test für degp-protease inhibitoren |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| AU2001287040A1 (en) | 2000-09-01 | 2002-03-13 | Biogen, Inc. | Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins |
| US7041479B2 (en) * | 2000-09-06 | 2006-05-09 | The Board Of Trustess Of The Leland Stanford Junior University | Enhanced in vitro synthesis of active proteins containing disulfide bonds |
| CZ304484B6 (cs) | 2000-12-14 | 2014-05-21 | Genentech, Inc. | Bakteriální hostitelské kmeny a způsob tvorby polypeptidu |
| EP1356052B1 (en) | 2000-12-14 | 2008-08-20 | Genentech, Inc. | Production of full antibodies in procaryotic cells |
| TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| ATE382053T1 (de) | 2001-08-27 | 2008-01-15 | Genentech Inc | System zur antikörperexpression und- synthese |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| DE60230918D1 (de) | 2001-11-16 | 2009-03-05 | Biogen Idec Inc | Polycistronische expression von antikörpern in cho zellen |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| US7608429B2 (en) * | 2002-10-31 | 2009-10-27 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| PT1570267E (pt) | 2002-12-03 | 2012-01-03 | Ucb Pharma Sa | Ensaio para a identificação de células produtoras de anticorpos |
| DE602004006831T2 (de) | 2003-01-09 | 2008-02-14 | Genentech, Inc., South San Francisco | Reinigung von polypeptiden |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| NZ544486A (en) | 2003-06-13 | 2009-04-30 | Biogen Idec Inc | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| NZ580688A (en) | 2003-07-26 | 2012-03-30 | Biogen Idec Inc | Method of designing altered antibodies having improved antigen-binding affinity |
| JP5102028B2 (ja) | 2004-07-26 | 2012-12-19 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗ｃｄ１５４抗体 |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| GB0425534D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
| EP2125894B1 (en) | 2007-03-22 | 2018-12-19 | Biogen MA Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| US7662587B1 (en) | 2009-03-05 | 2010-02-16 | E. I. Du Pont De Nemours And Company | Gene knockout mutations that increase peptide production |
| SI2993231T1 (sl) | 2009-09-24 | 2018-10-30 | Ucb Biopharma Sprl | Bakterijski sev za izražanje rekombinantnega proteina, ki ima proteazno deficientno DEGP-zadrževalno šaperonsko aktivnost, ter onesposobljena gena TSP in PTR |
| US8470552B2 (en) | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| MX2012005168A (es) | 2009-11-05 | 2012-06-08 | Genentech Inc | Metodos y composicion para secrecion de polipeptidos heterologos. |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000588D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
| WO2013007388A1 (en) | 2011-07-13 | 2013-01-17 | Ucb Pharma, S.A. | Bacterial host strain expressing recombinant dsbc |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
-
2010
- 2010-07-27 GB GBGB1012599.5A patent/GB201012599D0/en not_active Ceased
-
2011
- 2011-07-27 CN CN201180036417.8A patent/CN103189385B/zh active Active
- 2011-07-27 KR KR1020137004911A patent/KR101944121B1/ko active Active
- 2011-07-27 BR BR112013000177-1A patent/BR112013000177B1/pt not_active IP Right Cessation
- 2011-07-27 PL PL11745810T patent/PL2598516T3/pl unknown
- 2011-07-27 JP JP2013521208A patent/JP5935222B2/ja active Active
- 2011-07-27 WO PCT/GB2011/001129 patent/WO2012013930A2/en not_active Ceased
- 2011-07-27 ES ES11745810.9T patent/ES2537877T3/es active Active
- 2011-07-27 AU AU2011284548A patent/AU2011284548B2/en active Active
- 2011-07-27 HU HUE11745810A patent/HUE026049T2/en unknown
- 2011-07-27 CA CA2804099A patent/CA2804099C/en active Active
- 2011-07-27 SG SG2014005441A patent/SG196862A1/en unknown
- 2011-07-27 RS RS20150429A patent/RS54085B1/sr unknown
- 2011-07-27 SI SI201130516T patent/SI2598516T1/sl unknown
- 2011-07-27 HR HRP20150639TT patent/HRP20150639T1/hr unknown
- 2011-07-27 PT PT117458109T patent/PT2598516E/pt unknown
- 2011-07-27 SG SG2013001318A patent/SG186974A1/en unknown
- 2011-07-27 ME MEP-2015-94A patent/ME02162B/me unknown
- 2011-07-27 US US13/812,350 patent/US9751930B2/en active Active
- 2011-07-27 DK DK11745810.9T patent/DK2598516T3/da active
- 2011-07-27 MX MX2013000899A patent/MX337184B/es active IP Right Grant
- 2011-07-27 EP EP11745810.9A patent/EP2598516B8/en active Active
-
2012
- 2012-12-31 IL IL224044A patent/IL224044A/en active IP Right Grant
-
2015
- 2015-06-18 SM SM201500142T patent/SMT201500142B/xx unknown
- 2015-06-23 CY CY20151100535T patent/CY1116526T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02162B (me) | Proces prečišćavanja proteina | |
| JP6039828B2 (ja) | モノクローナル抗体の精製方法 | |
| IL296682B1 (en) | Method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists | |
| CN113912710B (zh) | 抗新型冠状病毒n蛋白的单克隆抗体及其应用 | |
| BR112014015101A8 (pt) | métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos | |
| HRP20180226T1 (hr) | Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc | |
| RU2016119152A (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| NZ627668A (en) | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography | |
| NZ592095A (en) | Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography | |
| JP2018085988A5 (me) | ||
| PE20141660A1 (es) | PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA | |
| PE20121646A1 (es) | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica | |
| FI3390451T3 (fi) | Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan | |
| RU2017125758A (ru) | Антитела к с5 и способы их применения | |
| RU2016108828A (ru) | Способы и композиции, включающие очищенные рекомбинантные полипептиды | |
| JP2019522961A5 (me) | ||
| JP2016539176A5 (me) | ||
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| BR112012017124A2 (pt) | método de modificação polipeptídica para purificação de multímeros polipeptídicos | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| RU2013140350A (ru) | Антитела против человеческого il33r и их применение | |
| RU2014145536A (ru) | Антитело против adamts-5, его производные и их применение | |
| RU2020132716A (ru) | Способы очистки антител | |
| JP2015536347A5 (me) | ||
| HRP20240585T1 (hr) | Postupci uzgoja stanica |